Literature DB >> 26708101

Programmed Nanococktail for Intracellular Cascade Reaction Regulating Self-Synergistic Tumor Targeting Therapy.

Wei-Hai Chen1, Guo-Feng Luo1, Wen-Xiu Qiu1, Qi Lei1, Sheng Hong1, Shi-Bo Wang1, Di-Wei Zheng1, Cheng-Hui Zhu1, Xuan Zeng1, Jun Feng1, Si-Xue Cheng1, Xian-Zheng Zhang1,2.   

Abstract

In this work, a ZnO based nanococktail with programmed functions is designed and synthesized for self-synergistic tumor targeting therapy. The nanococktail can actively target tumors via specific interaction of hyaluronic acid (HA) with CD44 receptors and respond to HAase-rich tumor microenvironment to induce intracellular cascade reaction for controlled therapy. The exposed cell-penetrating peptide (R8) potentiates the cellular uptake of therapeutic nanoparticles into targeted tumor cells. Then ZnO cocktail will readily degrade in acidic endo/lysosomes and induce the production of desired reactive oxygen species (ROS) in situ. The destructive ROS not only leads to serious cell damage but also triggers the on-demand drug release for precise chemotherapy, thus achieving enhanced antitumor efficiency synergistically. After tail vein injection of ZnO cocktail, a favorable tumor apoptosis rate (71.2 ± 8.2%) is detected, which is significantly superior to that of free drug, doxorubicin (12.9 ± 5.2%). Both in vitro and in vivo studies demonstrate that the tailor-made ZnO cocktail with favorable biocompatibility, promising tumor specificity, and self-synergistically therapeutic capacity opens new avenues for cancer therapy.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  cascade reaction; self-synergistic therapy; targeted therapies; tumor targeting

Mesh:

Substances:

Year:  2015        PMID: 26708101     DOI: 10.1002/smll.201503280

Source DB:  PubMed          Journal:  Small        ISSN: 1613-6810            Impact factor:   13.281


  7 in total

1.  Smart Cu(II)-aptamer complexes based gold nanoplatform for tumor micro-environment triggered programmable intracellular prodrug release, photodynamic treatment and aggregation induced photothermal therapy of hepatocellular carcinoma.

Authors:  Da Zhang; Aixian Zheng; Juan Li; Ming Wu; Lingjie Wu; Zuwu Wei; Naishun Liao; Xiaolong Zhang; Zhixiong Cai; Huanghao Yang; Gang Liu; Xiaolong Liu; Jingfeng Liu
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

Review 2.  ROS-responsive drug delivery systems.

Authors:  Jing Liang; Bin Liu
Journal:  Bioeng Transl Med       Date:  2016-07-05

3.  A multistage assembly/disassembly strategy for tumor-targeted CO delivery.

Authors:  Jin Meng; Zhaokui Jin; Penghe Zhao; Bin Zhao; Mingjian Fan; Qianjun He
Journal:  Sci Adv       Date:  2020-05-15       Impact factor: 14.136

4.  Cooperation of endogenous and exogenous reactive oxygen species induced by zinc peroxide nanoparticles to enhance oxidative stress-based cancer therapy.

Authors:  Li-Sen Lin; Jun-Feng Wang; Jibin Song; Yijing Liu; Guizhi Zhu; Yunlu Dai; Zheyu Shen; Rui Tian; Justin Song; Zhantong Wang; Wei Tang; Guocan Yu; Zijian Zhou; Zhen Yang; Tao Huang; Gang Niu; Huang-Hao Yang; Zhi-Yi Chen; Xiaoyuan Chen
Journal:  Theranostics       Date:  2019-09-23       Impact factor: 11.556

5.  Reactive Oxygen Species-Responsive Nanococktail With Self-Amplificated Drug Release for Efficient Co-Delivery of Paclitaxel/Cucurbitacin B and Synergistic Treatment of Gastric Cancer.

Authors:  Lijun Pang; Lei Zhang; Hong Zhou; Ling Cao; Yueqin Shao; Tengyun Li
Journal:  Front Chem       Date:  2022-03-04       Impact factor: 5.221

Review 6.  Applications of the ROS-Responsive Thioketal Linker for the Production of Smart Nanomedicines.

Authors:  Arianna Rinaldi; Riccardo Caraffi; Maria Vittoria Grazioli; Natalia Oddone; Luciana Giardino; Giovanni Tosi; Maria Angela Vandelli; Laura Calzà; Barbara Ruozi; Jason Thomas Duskey
Journal:  Polymers (Basel)       Date:  2022-02-11       Impact factor: 4.329

7.  A pH/ROS cascade-responsive and self-accelerating drug release nanosystem for the targeted treatment of multi-drug-resistant colon cancer.

Authors:  Na Chang; Yufei Zhao; Ning Ge; Liting Qian
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.819

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.